Cancer Stem Cell Targeting Antibody Production Service
Background Service Workflow Highlights Published Data FAQs Contact
Are you currently facing the persistent challenges of cancer recurrence and treatment resistance? Creative Biolabs' cancer stem cell targeting antibody production service helps you overcome these hurdles by enabling the development of highly specific antibodies for both diagnostic and therapeutic applications. Through our innovative antibody engineering and advanced radiolabeling techniques, we empower your research to precisely target the elusive cancer stem cell population.
Introduction
Cancer stem cells (CSCs) represent a formidable challenge in oncology, driving tumor initiation, metastasis, and resistance to conventional therapies. Their unique properties necessitate highly specific targeting strategies. Creative Biolabs' service focuses on developing antibodies against critical CSC markers like CD133 and ALDH, enabling both precise diagnostic imaging and potent immunotherapeutic interventions. This approach is supported by published data demonstrating the efficacy of such targeted antibodies in preclinical models, paving the way for next-generation cancer treatments.
Fig.1 Different therapeutic methods can be used to target cancer stem cells (CSCs).1,3
Cancer Stem Cell Targeting Antibody Production Service at Creative Biolabs
Creative Biolabs delivers comprehensive solutions for developing antibodies specifically designed to recognize and bind to cancer stem cell (CSC) antigens. Our service provides researchers and pharmaceutical companies with high-affinity, high-specificity antibodies crucial for advancing novel diagnostic imaging agents and targeted immunotherapies. This includes collaborating to identify and validate novel cell surface markers unique to cancer stem cells and providing therapeutic antibody production against these highly tumorigenic and drug-resistant cell populations. Customers can expect meticulously characterized antibody constructs, ready for preclinical and potential clinical translation.
Service Process
Key Advantages
- Tailored Antibody Design & Production: We offer fully customized services for your specific CSC antigen targets, allowing for the development of diverse antibody formats, including full IgGs, scFv, and scFv-Fc fragments, precisely engineered for your diagnostic or therapeutic applications.
- Cutting-Edge Discovery Platforms: Leveraging advanced technologies such as phage display and single B cell sorting, we efficiently discover and select high-affinity, high-specificity antibody candidates, ensuring optimal binding to your target CSC population.
- Comprehensive Antibody Engineering: Our expertise extends to humanization, affinity maturation, and the integration of specific modifications, enhancing antibody performance and clinical translatability while minimizing immunogenicity.
- Rigorous Quality Control & Characterization: Every antibody undergoes extensive in vitro validation, including detailed binding kinetics, specificity assays, and functional assessments, ensuring superior quality and performance.
- Seamless Preclinical Integration: We provide antibodies optimized for preclinical studies, enabling clear delineation of CSC-expressing tumors and facilitating the development of companion diagnostics.
- Support for Combination Therapies: Our antibodies are designed to integrate seamlessly into advanced therapeutic strategies, including synergistic approaches with immune checkpoint blockade, maximizing anti-tumor efficacy.
- Expert Consultation & Project Management: Benefit from our teams over 20 years of experience in biology and oncology, providing expert guidance and dedicated project management from concept to delivery.
Representative Data
Summary: To facilitate emerging cancer stem cell-targeted therapies, researchers developed Zinc-labeled probes targeting the cancer stem cell antigen CD133 using fully human antibodies and antibody scFv-Fc scaffolds. Three probes were synthesized with radiochemical purities exceeding 97%. In vitro binding assays revealed low-nanomolar binding affinities for CD133. Biodistribution studies demonstrated that the probes exhibited the highest tumor uptake with minimal off-target accumulation, outperforming IgG-based counterparts, which showed delayed tumor uptake and higher liver retention.
Fig.2 Preparation of conjugates.2,3
FAQs
What types of cancer stem cell antigens can Creative Biolabs target?
We specialize in targeting diverse CSC-specific antigens, including CD133, CD44, and EpCAM. For novel targets, our team can assess suitability and develop custom strategies. Discuss your specific antigen with our experts.
How do your CSC-targeting antibodies compare to traditional cancer therapies?
Our antibodies specifically target CSCs, which are often resistant to chemo/radiotherapy. This precision reduces off-target effects, overcomes resistance, and enables more effective, less toxic treatments. We also offer diagnostic probes for non-invasive visualization of these cells.
Are the antibodies produced suitable for both diagnostic and therapeutic applications?
Yes. Our versatile service produces antibodies optimized for diverse uses: ImmunoPET imaging, therapeutics like ADCs, or immune cell recruitment (e.g., vaccines). We tailor the format and modifications to your needs.
What precautions ensure antibody specificity and safety?
We use rigorous in vitro / in vivo characterization: binding assays, flow cytometry, and preclinical biodistribution studies. For therapeutics, we evaluate immunogenicity and off-target toxicity. Our fully human platforms minimize immune responses.
Why Choose Us?
Creative Biolabs is your trusted partner in advancing cancer research through highly specific and effective cancer stem cell targeting antibody solutions. Our commitment to scientific excellence and client success drives us to deliver innovative tools for both diagnostic precision and therapeutic breakthroughs.
Contact us for more information and to discuss your project.
References
- Santamaria, Silvia et al. "Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible?" Frontiers in immunology, vol. 8 (2017): 1509. DOI: https://doi.org/10.3389/fimmu.2017.01509
- Wyszatko, Kevin et al. "89Zr-labeled ImmunoPET targeting the cancer stem cell antigen CD133 using fully-human antibody constructs." EJNMMI research, vol. 14,1 (2024): 29. DOI: https://doi.org/10.1186/s13550-025-01331-6
- Distributed under Open Access License CC BY 4.0, without modification.
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
